Cas No.: | 811803-05-1 |
Chemical Name: | Apatinib free base |
Synonyms: | Apatinib (YN968D1);Apatinib;3-Pyridinecarboxamide, N-[4-(1-cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]-;Aptinib;N-(4-(1-Cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide;N-(4-(1-Cyanocyclopentyl)phenyl)-2-(pyridin-4-ylmethylamino)nicotinamide |
SMILES: | CS(O)(=O)=O.C1CC(C2=CC=C(NC(C3=CC=CN=C3NCC3=CC=NC=C3)=O)C=C2)(C#N)CC1 |
Formula: | C24H23N5O |
M.Wt: | 397.482 |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC50=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the treatment of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC50s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ[1][2][3]. |